Guangzhou Anhao Pharmaceuticals

Guangzhou Anhao Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, dedicated to developing innovative small molecule drugs for liver diseases and metabolic disorders. The company's primary focus is on creating functional cures for chronic hepatitis B (CHB) and effective treatments for non-alcoholic steatohepatitis (NASH). Its lead program, AH-01, is an orally administered Toll-like receptor 7 (TLR7) agonist currently in Phase 2 clinical trials, designed to stimulate the innate immune system to clear viral infections. Additionally, the company is developing AH-03, a thyroid hormone receptor beta (THR-beta) agonist for the treatment of NASH. Anhao Pharmaceuticals emphasizes medicinal chemistry and prodrug technologies to optimize the therapeutic index of its candidates.